Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo
Zola Matuvanga, T.; MARIEN, J.; LARIVIERE, Y.; Osangir, B.; Milolo, S.; Meta, R.; Esanga, E.; Maketa, V.; Matangila, J.; Mitashi, P.; Ahuka Mundeke, S.; Muhindo-Mavoko, H.; Muyembe Tamfum, J.-J.; Van Damme, P.; Van geertruyden, J.-P.
Show abstract
IntroductionA serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens. MethodsSerum samples were collected in a cohort of HCPs and frontliners (n=698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay. ResultsThe seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7-2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0 - 1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5-10.9) samples using FANG ELISA. ConclusionIn contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Diagnostic serology test comparison for Q fever and Rift Valley fever in humans and livestock from pastoral communities 95%
- Paving the way for human vaccination against Rift Valley fever virus: A systematic literature review of RVFV epidemiology from 1999 to 2021 94%
- The epidemiology of Mayaro virus in the Americas: A systematic review and key parameter estimates for outbreak modelling 94%
Similar papers in this journal
- Have you heard of Rift Valley fever? Findings from a multi-country study in East and Central Africa 95%
- High seroprevalence of Immunoglobulin G (IgG) and IgM antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out in western Kenya 94%
- Integrating post-validation surveillance of lymphatic filariasis with the WHO STEPwise approach to non-communicable disease risk factor surveillance in Niue, a study protocol 94%
Similar papers in this journal
- Effectiveness of Typhoid Conjugate Vaccine in Zimbabwe used in response to an outbreak among children and young adults: a matched case control study 94%
- Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults 94%
- Cellular and Humoral Immunity to Ebola Zaire Glycoprotein and Viral Vector Proteins Following Immunization with Recombinant Vesicular Stomatitis Virus-Based Ebola Vaccine (rVSVΔG-EBOV-GP) 94%
Similar papers in this journal
- SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia 95%
- Enhanced surveillance of monkeypox in Bas-Uele, Democratic Republic of Congo: the limitations of symptom-based case definitions. 95%
- Prevalence of IgG and IgM to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone and Uganda: A Longitudinal Study 95%
Similar papers in this journal
- Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine 94%
- SARS-CoV-2 seroassay optimization and performance in a population with high background reactivity in Mali 94%
- A bivalent Adenovirus-Vectored Vaccine induces a measurable humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.